Climb Bio, Inc.
CLYM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001768446
In the last 90 days, Climb Bio, Inc. insiders filed 0 open-market purchases and 1 sale; 108 institutions reported holding it in 13F filings for Q2 2026, worth $734.3M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Climb Bio, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- +1 vs. Q2 2023
- Shares held
- 16.7M
- −1.84K (0.0%) vs. Q2 2023
- Total value
- $44.0M
- −$2.85M (−6.1%) vs. Q2 2023
- New holders
- 2
- 6 more added
- Sold out
- 1
- 8 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLYM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 108 | $734.3M |
| Q1 2026 | 80 | $221.2M |
| Q4 2025 | 65 | $157.4M |
| Q3 2025 | 68 | $89.7M |
| Q2 2025 | 69 | $61.9M |
| Q1 2025 | 76 | $63.4M |
| Q4 2024 | 80 | $100.3M |
| Q3 2024 | 71 | $278.2M |
| Q2 2024 | 47 | $354.8M |
| Q1 2024 | 21 | $46.2M |
| Q4 2023 | 23 | $45.5M |
| Q3 2023 | 23 | $44.0M |
| Q2 2023 | 22 | $46.8M |
| Q1 2023 | 19 | $48.4M |
| Q4 2022 | 20 | $61.0M |
| Q3 2022 | 22 | $47.8M |
| Q2 2022 | 29 | $45.7M |
| Q1 2022 | 43 | $146.8M |
| Q4 2021 | 35 | $181.8M |
| Q3 2021 | 32 | $310.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Climb Bio, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 56 | $0 | 0.00% | −69−55.2% | Reduced |
| Wells Fargo & Company | 45 | $118 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 89 | $234 | 0.00% | +89 | New |
| Qube Research & Technologies Ltd | 981 | $2.59K | 0.00% | +981 | New |
| Bank of America Corp | 1,390 | $3.66K | 0.00% | +471+51.3% | Added |
| Morgan Stanley | 1,709 | $4.50K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,896 | $10.2K | 0.00% | −858−18.0% | Reduced |
| Advisor Group Holdings, Inc. | 8,333 | $21.9K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 11,182 | $29.4K | 0.00% | 00.0% | Unchanged |
| Chicago Partners Investment Group LLC | 12,806 | $32.8K | 0.00% | −3,764−22.7% | Reduced |
| Stifel Financial Corp | 14,650 | $38.5K | 0.00% | −250−1.7% | Reduced |
| State Street Corp | 21,700 | $57.3K | 0.00% | +1,900+9.6% | Added |
| Tudor Investment Corp Et Al | 29,704 | $78.1K | 0.00% | −20.0% | Reduced |
| BlackRock Inc. | 31,311 | $82.3K | 0.00% | −581−1.8% | Reduced |
| Bridgeway Capital Management, LLC | 55,223 | $145.8K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 58,336 | $154.0K | 0.00% | −6,595−10.2% | Reduced |
| Geode Capital Management, LLC | 66,626 | $176.0K | 0.00% | +2,612+4.1% | Added |
| Atom Investors LP | 78,886 | $207.5K | 0.05% | 00.0% | Unchanged |
| Silverarc Capital Management, LLC | 121,110 | $318.5K | 0.12% | −372,979−75.5% | Reduced |
| Vanguard Group Inc | 309,821 | $814.8K | 0.00% | +35,304+12.9% | Added |
| Driehaus Capital Management LLC | 811,680 | $2.13M | 0.03% | +1,087+0.1% | Added |
| BML Capital Management, LLC | 1,938,263 | $5.10M | 4.70% | +355,093+22.4% | Added |
| Ra Capital Management, L.P. | 13,150,849 | $34.6M | 0.68% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −14,279−100.0% | Sold out |